3
Announcements
Trials
Browse
Landscape
Status
Approved for marketing
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
CNS
1
Conditions
Recurrence
1
Pathologic Processes
1
Oligodendroglioma
1
Neuroectodermal Tumors
1
Neoplasms, Neuroepithelial
1
Neoplasms, Nerve Tissue
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Histologic Type
1
Neoplasms
1
Glioma
1
Disease Attributes
1
Astrocytoma
1
Interventions
Crizotinib
2
Bone Marrow Transplantation
2
3-Iodobenzylguanidine
2
vorasidenib
1
tucatinib
1
tovorafenib
1
tazemetostat
1
taletrectinib
1
olaparib
1
nirogacestat
1
glucarpidase
1
enzalutamide
1
denileukin diftitox
1
copanlisib
1
balstilimab
1
atezolizumab
1
adagrasib
1
Proton Pump Inhibitors
1
Peripheral Blood Stem Cell Transplantation
1
Nivolumab
1
LY3023414
1
Hydrocortisone
1
Carboxypeptidases
1
Antibodies, Bispecific
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Expanded_access
×
Neoplasms
×
vorasidenib
×
Clear all
NCT05592743
2024-11-05
Vorasidenib Expanded Access Program
Servier
Approved for marketing